Dashboard
Manage Tickers

NNVCNANOVIRICIDES, INC.

NYSE nanoviricides.com


$ 1.90 $ 0.06 (3.28 %)    

Friday, 10-May-2024 15:59:37 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 1.89
$ 1.78
$ 0.00 x 0
$ 0.00 x 0
$ 1.74 - $ 1.90
$ 1.00 - $ 2.13
184,873
na
22.2M
$ -0.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-14-2024 12-31-2023 10-Q
2 11-14-2023 09-30-2023 10-Q
3 10-13-2023 06-30-2023 10-K
4 05-15-2023 03-31-2023 10-Q
5 02-14-2023 12-31-2022 10-Q
6 11-14-2022 09-30-2022 10-Q
7 10-13-2022 06-30-2022 10-K
8 05-16-2022 03-31-2022 10-Q
9 02-14-2022 12-31-2021 10-Q
10 11-15-2021 09-30-2021 10-Q
11 10-12-2021 06-30-2021 10-K
12 05-14-2021 03-31-2021 10-Q
13 02-16-2021 12-31-2020 10-Q
14 11-16-2020 09-30-2020 10-Q
15 10-13-2020 06-30-2020 10-K
16 06-22-2020 03-31-2020 10-Q
17 02-14-2020 12-31-2019 10-Q
18 11-15-2019 09-30-2019 10-Q
19 08-23-2019 06-30-2019 10-K
20 05-15-2019 03-31-2019 10-Q
21 02-14-2019 12-31-2018 10-Q
22 11-14-2018 09-30-2018 10-Q
23 10-12-2018 06-30-2018 10-K
24 05-21-2018 03-31-2018 10-Q
25 02-20-2018 12-31-2017 10-Q
26 11-14-2017 09-30-2017 10-Q
27 09-28-2017 06-30-2017 10-K
28 05-15-2017 03-31-2017 10-Q
29 02-14-2017 12-31-2016 10-Q
30 11-14-2016 09-30-2016 10-Q
31 09-16-2016 06-30-2016 10-K
32 05-10-2016 03-31-2016 10-Q
33 02-09-2016 12-31-2015 10-Q
34 11-09-2015 09-30-2015 10-Q
35 09-14-2015 06-30-2015 10-K
36 05-15-2015 03-31-2015 10-Q
37 02-24-2015 12-31-2014 10-Q
38 11-14-2014 09-30-2014 10-Q
39 09-29-2014 06-30-2014 10-K
40 05-15-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

nanoviricides-reports-breakthrough-in-treating-airborne-viruses-boosting-lifespan-in-infected-mice
NanoViricides Reports Breakthrough in Trea...
05/08/2024 10:37:41

 NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that ...

ef-hutton-reiterates-buy-on-nanoviricides-maintains-65-price-target
EF Hutton Reiterates Buy on Nanoviricides,...
05/07/2024 13:51:38

EF Hutton analyst Tim Moore reiterates Nanoviricides (AMEX:NNVC) with a Buy and maintains $6.5 price target.

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
05/06/2024 16:31:16

nanoviricides-broad-spectrum-antiviral-nv-387-offers-protection-against-influenza-a-and-bird-flu
NanoViricides' Broad-Spectrum Antiviral NV...
05/06/2024 10:33:56

NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that t...

nanoviricides-reports-that-the-phase-i-nv-387-clinical-trial-is-completed-successfully-and-data-lock-is-expected-soon
NanoViricides Reports That The Phase I NV-...
04/30/2024 10:34:02

ef-hutton-reiterates-buy-on-nanoviricides-maintains-65-price-target
EF Hutton Reiterates Buy on Nanoviricides,...
02/16/2024 12:14:32

EF Hutton analyst Tim Moore reiterates Nanoviricides (AMEX:NNVC) with a Buy and maintains $6.5 price target.

nanoviricides-q2-eps-018-down-from-015-yoy-as-of-december-31-2023-we-had-cash-and-cash-equivalent-current-assets-balance-of-approximately-531m-additional-agreements-have-resulted-in-a-further-approximately-25m-available-cash
Nanoviricides Q2 EPS $(0.18) Down From $(0...
02/15/2024 11:44:36

Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.18) per share. This is a 20 percent decrease over losses of $(0.15) ...

nanoviricides-explains-that-the-demonstration-of-strong-safety-and-tolerability-of-nv-cov-2-oral-drug-products-has-implications-beyond-covid
NanoViricides Explains That The Demonstrat...
02/01/2024 11:26:46

nanoviricides-says-the-healthy-subjects-part-of-the-phase-1a1b-clinical-trial-of-nv-cov-2-was-completed-successfully-and-no-adverse-events-were-reported-in-any-of-the-ascending-dose-cohorts
NanoViricides Says The Healthy Subjects Pa...
01/29/2024 11:33:30

nanoviricides-has-completed-the-single-ascending-dose-part-of-the-phase-1a1b-human-trial-of-nv-cov-2-a-broad-spectrum-antiviral-drug-recruitment-for-the-multiple-ascending-dose-part-was-also-completed
NanoViricides Has Completed The Single-asc...
11/28/2023 11:47:47

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
08/22/2023 17:31:17

nanoviricides-reported-that-the-phase-1a1b-human-clinical-trial-of-nv-cov-2-the-companys-broad-spectrum-antiviral-drug-is-progressing-successfully
Nanoviricides Reported That The Phase 1a/1...
08/21/2023 10:52:24

The Company reports that its Indian collaborator and drug sponsor, Karveer Meditech Pvt. Ltd., India, has communicated that a...

12-health-care-stocks-moving-in-tuesdays-intraday-session
12 Health Care Stocks Moving In Tuesday's ...
07/11/2023 17:37:36

why-are-nanoviricides-shares-gaining-today
Why Are NanoViricides Shares Gaining Today
07/11/2023 16:51:10

NanoViricides Inc (NYSE: NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical...

why-better-therapeutics-are-trading-higher-by-51-here-are-20-stocks-moving-premarket
Why Better Therapeutics Are Trading Higher...
07/11/2023 12:33:53

Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on ...

nanoviricides-reports-effectiveness-of-antiviral-clinical-drug-candidate-nv-387-in-an-animal-model-of-lethal-lung-infection-with-respiratory-syncytial-virus
NanoViricides Reports Effectiveness Of Ant...
07/11/2023 10:50:02

nanoviricides-says-clinical-trial-of-broad-spectrum-antiviral-drug-nv-cov-2-is-progressing-well---nv-cov-2-is-positioned-to-fulfill-many-unmet-medical-needs
NanoViricides Says Clinical Trial Of Broad...
07/06/2023 14:35:21

NanoViricides, Inc. (NYSE American: NNVC) (the “Company”) reports that the clinical trial of its broad-spectrum antiviral drug ...

nanoviricides-says-clinical-trial-of-its-broad-spectrum-antiviral-drug-nv-cov-2-is-progressing-satisfactorily
NanoViricides Says Clinical Trial Of Its B...
07/06/2023 10:46:51

Following safety and tolerability evaluation in healthy persons for a single escalating dose of NV-CoV-2 Oral Syrup or NV-CoV-2...

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
06/02/2023 13:07:03

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
06/01/2023 17:31:50

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION